"МЕДИЦИНСКИЙ ЦЕНТР "MEREY" ФИЛИАЛ ТОО "ДЕНСАУЛЫҚ ӘЛЕМІ" МЕДИЦИНСКИЙ ЦЕНТР"
This is a company preview
Unlock the full report for 1 check — contacts, bank accounts, court cases, government contracts, arrests, licenses and PDF export.
Risks
0/17Комитет государственных доходов · Государственные закупки РК · АО ФНБ «Самрук-Казына» · АОО «НИШ»This assessment is informational and analytical only, based on our internal methodology and open sources; it is not an official government conclusion or a guarantee of reliability.
Procurement signals
Arrests & encumbrances
Enforcement proceedings
Certificates
Licenses and permits
Summary
Министерство юстиции РКActivities
86210 Общая врачебная практика
Общая врачебная практика
Contacts
Change history
Financial statements
PremiumPublic contracts
What it sells and where
Samruk-Kazyna procurement
Tender bids
Procurement as a customer
Assets
Bank accounts
Leadership
1- СА
Сактаганов Абзал Жолдыбекович
Director
Founders
Accreditations
Employees
Affiliated companies
PremiumDirector's involvement in other legal entities
Branches
Company networks
PremiumSimilar companies
Media mentions
Company summary
"МЕДИЦИНСКИЙ ЦЕНТР "MEREY" ФИЛИАЛ ТОО "ДЕНСАУЛЫҚ ӘЛЕМІ" МЕДИЦИНСКИЙ ЦЕНТР" (BIN 261041021687): Active legal entity, Almaty, registered in 2026. Main activity: healthcare. Enterprise category: small enterprise, up to 5 employees. No risk indicators for "МЕДИЦИНСКИЙ ЦЕНТР "MEREY" ФИЛИАЛ ТОО "ДЕНСАУЛЫҚ ӘЛЕМІ" МЕДИЦИНСКИЙ ЦЕНТР" were found in open registries. Director on record: Сактаганов Абзал Жолдыбекович. Registry data current as of November 3, 2026.
Data sources and disclaimer
Sources: Министерство юстиции РК, Комитет государственных доходов МФ РК, Верховный Суд РК, Портал государственных закупок РК, АО «Самрук-Казына», Бюро национальной статистики РК, Портал электронного лицензирования. Data is collected automatically and may lag behind primary sources; the absence of a record does not guarantee the absence of the fact. This is reference information and does not replace an official extract. Methodology: SafeDeal editorial policy.